ReviewFrontiers in pharmacology2026
Protease-activated receptor 1 in diabetes and its chronic complications: signaling mechanisms and emerging therapeutic advances.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a systemic metabolic disorder characterized by chronic hyperglycemia, which can affect the kidneys, retina, peripheral nerves, and cardiovascular system, ultimately leading to multiple chronic complications. Protease-activated receptor 1 (PAR1) is a G protein-coupled receptor activated through canonical cleavage, such as thrombin-mediated cleavage, and non-canonical cleavage, such as cleavage by activated protein C or matrix metalloproteinase-1. These activation modes initiate diverse downstream signaling pathways, including Gαq/PLC-β/PKC, Gα12/13/Rho, and β-arrestin-dependent signaling, and contribute to inflammation, fibrosis, angiogenesis, and apoptosis. This review summarizes the role of PAR1 in the pathogenesis of type 2 diabetes mellitus (T2DM), focusing on its effects on endothelial insulin resistance, adipose tissue inflammation, and brown adipose tissue dysfunction. We further discuss the pathogenic mechanisms of PAR1 in diabetic kidney disease, diabetic retinopathy, diabetic peripheral neuropathy, and diabetic cardiovascular disease. This review also outlines recent advances in PAR1-targeted therapies, including orthosteric antagonists such as vorapaxar, biased signaling modulators such as 3K3A-APC and parmodulins, and intracellular inhibitors such as PZ-128. Their therapeutic potential and current challenges in antithrombotic therapy and target-organ protection are also discussed, with the aim of informing more precise strategies for preventing and treating DM and its chronic complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.